Is Ascentage Pharma Group International (AAPG) a Buy, Sell, or Hold?
Ascentage Pharma Group International
NASDAQ:AAPG
$19.24 USD
-$0.38 (-1.94%)
- Volume
- 3.06K
- Average Volume
- 10.98K
- Market Capitalization
- $1.79B
- P/E Ratio
- -9.41
- Dividend Yield
- 0.00%
- Price Target
- $40.00
- Year High
- $48.45
- Year Low
- $16.36
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.79
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Dajun Yang |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | AAPG |
| CUSIP | 04390B105 |
| CIK | 0002023311 |
| Web | https://www.ascentage.com |
| Phone | 86 512 8555 7777 |
| Currency | USD |
| Employees | 767 |
| Country | CN |
Liquidity
| Debt-to-Equity Ratio | 1.49 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.79 |
| Quick Ratio | 1.77 |
| Cash Ratio | 1.50 |
Sales & Book Value
| Annual Sales | $558.48M |
| Price / Sales | 21.31 |
| Cash Flow | -13.39 |
| Price / Cash Flow | -9.76 |
| Price / Book | 9.10 |
Price Target and Rating
| Average Stock Price Forecast | $40.00 |
| High Stock Price Forecast | $40.00 |
| Low Stock Price Forecast | $40.00 |
| Forecast Upside/Downside | -51.90% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 1 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-13.56 |
| Trailing P/E Ratio | -9.41 |
| PEG Ratio | 0.05 |
| P/E Growth | 0.05 |
| Net Income | $-1.21B |
| Net Margin | -216.74% |
| Pretax Margin | -215.56% |
| Return on Equity | -123.61% |
| Return on Assets | -31.03% |
Financials Score
| AltmanZ Score | 2.34 |
| Piotroski Score | 4.00 |
| Working Capital | 1.3B |
| Total Assets | 3.97B |
| Ebit | -1.57B |
| Market Cap | 12.56B |
| Total Liabilities | 2.63B |
Poll Results
About Ascentage Pharma Group International (NASDAQ:AAPG) Stock
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential fo ... r both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.
2026-07-09 10:56:11
The consensus price target hints at a 152.2% upside potential for Ascentage Pharma Group International - Unsponsored ADR (AAPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
2026-06-14 19:30:00
ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026.
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
2026-05-31 19:30:00
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced results from a Phase Ib study evaluating olverembatinib (HQP1351), the company's core product, in combination with bispecific T-cell engager antibody (immunotherapy) blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (PhBCP-ALL) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
2026-05-31 19:30:00
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced that the Company presented its first dataset of alrizomadlin (APG-115), an MDM2-p53 inhibitor from the Company's apoptosis-targeted pipeline, as monotherapy or in combination with lisaftoclax (APG-2575) in pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs), in a rapid oral presentation at the 62nd American Society of Clinical Oncology (ASCO) Annual Meeting.
2026-05-31 19:30:00
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
2026-05-31 19:30:00
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced that the Company presented its first dataset of alrizomadlin (APG-115), an MDM2-p53 inhibitor from the Company's apoptosis-targeted pipeline, as monotherapy or in combination with lisaftoclax (APG-2575) in pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs), in a rapid oral presentation at the 62nd American Society of Clinical Oncology (ASCO) Annual Meeting.
2026-05-31 19:30:00
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
2026-05-31 19:30:00
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced results from a Phase Ib study evaluating olverembatinib (HQP1351), the company's core product, in combination with bispecific T-cell engager antibody (immunotherapy) blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Frequently Asked Questions
-
What is the current Ascentage Pharma Group International (AAPG) stock price?
-
Ascentage Pharma Group International(NASDAQ:AAPG) stock price is $19.24 in the last trading session. During the trading session, AAPG stock reached the peak price of $48.45 while $16.36 was the lowest point it dropped to. The percentage change in AAPG stock occurred in the recent session was --1.94% while the dollar amount for the price change in AAPG stock was -$-0.38.
-
AAPG's industry and sector of operation?
-
The NASDAQ listed AAPG is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AAPG?
-
Manish Tandon | SVP of Business Development
Chongdong Fu | Senior Vice President & Head of CMC
Dajun Yang | Co-Founder, Chairman & Chief Executive Officer
Shaomeng Wang | Co-Founder, Chief Scientific Advisor & Non-Executive Director
Veet Misra | Chief Financial Officer -
How many employees does AAPG have?
-
Number of AAPG employees currently stands at 767. AAPG operates from Suzhou Industrial Park, Suzhou, JS 215000, CN.
-
Link for AAPG official website?
-
Official Website of AAPG is: https://www.ascentage.com
-
How do I contact AAPG?
-
AAPG could be contacted at phone #86 512 8555 7777 and can also be accessed through its website. AAPG operates from Suzhou Industrial Park, Suzhou, JS 215000, CN.
-
How many shares of AAPG are traded daily?
-
The average number of AAPG shares traded daily for last 3 months was 10.98K.
-
What is the market cap of AAPG currently?
-
The market value of AAPG currently stands at $1.79B with its latest stock price at $19.24